60. 再生不良性貧血 Aplastic anemia Clinical trials / Disease details


臨床試験数 : 235 薬物数 : 384 - (DrugBank : 83) / 標的遺伝子数 : 42 - 標的パスウェイ数 : 159

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04439006
(ClinicalTrials.gov)
October 23, 202017/6/2020Ibrutinib for the Treatment of COVID-19 in Patients Requiring HospitalizationRandomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-InAplastic Anemia;Hematopoietic and Lymphoid Cell Neoplasm;Malignant Solid Neoplasm;Monoclonal B-Cell Lymphocytosis;Monoclonal Gammopathy of Undetermined Significance;Myelodysplastic Syndrome;Symptomatic COVID-19 Infection Laboratory-ConfirmedOther: Best Practice;Drug: IbrutinibJennifer WoyachJanssen Scientific Affairs, LLCActive, not recruiting18 YearsN/AAll10Phase 2United States